【24h】

Prostate brachytherapy: New techniques, new indications

机译:前列腺近距离放射治疗:新技术,新迹象

获取原文
获取原文并翻译 | 示例
       

摘要

Prostate brachytherapy has been for a long time one of the standard treatments for low risk prostate cancer, with high rates of biochemical control and low levels of urinary and sexual late toxicity compared to other available techniques, namely external beam radiotherapy and radical prostatectomy. The aim of this article is to review the recent innovations of prostate brachytherapy, which suggest a bright future for the technique. We will discuss the extension of indications of permanent implant brachytherapy to favorable intermediate-risk patients, the use of novel isotopes such as Palladium 103 and Cesium 131, and the benefit of brachytherapy as a boost following external beam radiotherapy for intermediate and high-risk patients. We will also discuss the rise of high dose rate brachytherapy, as a boost or monotherapy, the increasing use of MRI for patient selection and treatment planning, as well as the development of brachytherapy as a means of focal therapy. (C) 2018 Societe francaise de radiotherapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved.
机译:与其他可用技术相比,前列腺术前列腺癌的前列腺术术一直是长期的低风险前列腺癌的标准治疗方法,具有高生物化控制和尿液和性晚期毒性。本文的目的是审查最近的前列腺近距离放射治疗的创新,这表明该技术的光明未来。我们将讨论永久植入物近距离放射治疗到有利的中性风险患者的延伸,使用新颖的同位素如钯103和铯131,以及在外部光束放射治疗中间和高风险患者的外梁放射后的增压的益处。我们还将讨论高剂量率近距离放射治疗的兴起,作为提升或单一疗法,越来越多地利用MRI用于患者选择和治疗计划,以及近距离放射治疗的发育作为焦点治疗。 (c)2018 Societe Francaise de Radiotherapie Oncologique(SFRO)。由Elsevier Masson SA出版。版权所有。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号